RA Capital Management Exits Position in Avidity Biosciences, Inc. (RNA)

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and the RA Capital Healthcare Fund, L.P., filed a Schedule 13G/A on May 15, 2026, indicating they have completely exited their position in Avidity Biosciences, Inc. (RNA). The reporting persons previously held 8,641,031 shares, representing a significant stake in the company. As of the event date of March 31, 2026, the aggregate number of shares beneficially owned by all reporting persons is zero, resulting in a 0.0% ownership stake. This filing marks the third amendment to their original disclosure and confirms that the reporting persons no longer hold any voting or dispositive power over the issuer's common stock. The exit was reported under Rule 13d-1(c), certifying that the securities were not held for the purpose of changing or influencing the control of the issuer. The principal business office for the reporting entities remains located in Boston, Massachusetts.